ESTRO 2024 - Abstract Book

S698

Clinical - Breast

ESTRO 2024

53.5% received chemotherapy, 12.6% trastuzumab, 24.0% tamoxifen, 45.7% aromatase inhibitors, 12.2% tamoxifen followed by aromatase inhibitors and 2.0% LHRH antagonists.

With a median follow up of 6 years, a total of 1 382 patients reported at least one cardiac event during follow-up, including 139 myocardial infarctions (10.1%), 27 ventricular dysfonctions (2.0%), 604 rhythm disorders (43.7%), 21 conduction disorders (1.5%), 32 pericarditis (2.3%), 29 myocarditis (2.1%) and 253 valvular diseases (18.3%). 290 patients had died of any cause. The univariate analysis showed a significant association between cardiac event and the following factors: age at diagnosis, menopausal status, history of cardiac event, history of hypertension, smoking, obesity, endocrine therapy and Trastuzumab. Multivariable analysis is presented in Table 1. Compared to patients with right-sided tumors non irradiated, there was small but statistically nonsignificant increased odds-ratio (OR) of 1.27 (95% CI: 0.83 – 1.93), 1.08 (95% CI: 0.78 – 1.51), and 1.21 (95% CI: 0.87 – 1.68) for patients with left-sided tumor non-irradiated, right-sided tumors irradiated and left-sided tumors irradiated, respectively. Significant risk factors included history of cardiac event (OR = 4.45, 95% CI: 3.83 – 5.18), trastuzumab (OR = 1.38, 95% CI: 1.15 – 1.66), progesterone receptors positivity (OR = 1.19, 95% CI: 1.01 – 1.40) and obesity (OR = 1.18, 95% CI: 1.02 – 1.37).

Conclusion: